Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing

• US 6,534,293 B1
• Filed: 01/05/2000
• Issued: 03/18/2003
• Est. Priority Date: 01/06/1999
• Status: Expired due to Term

• Current Assignee: Cornell Research Foundation Incorporated (Cornell University), Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Original Assignee: Cornell Research Foundation Incorporated (Cornell University), Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Inventors: Zirvi, Monib, Paty, Philip B., Gerry, Norman P., Liu, Jianzhao, Kirk, Brian W., Barany, Francis
• Primary Examiner(s): Whisenant, Ethan C.
• Assistant Examiner(s): LU, FRANK WEI MIN
• Application Number:
  US09/478,189
• Time in Patent Office: 1,168 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 435/183, 435/465, 435/252.3, 435/320.1, 435/283.1, 435/287.1, 435/287.2, 436/94, 536/23.1, 536/24.3, 536/24.33, 536/25.3
• US Class Current: 435/91.2
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6841 In situ hybridisation
• CPC Class Codes: C12Q 1/6855 Ligating adaptors
• CPC Class Codes: C12Q 1/6874 involving nucleic acid arrays, e.g. sequencing by hybridisation
• CPC Class Codes: C12Q 2521/301 Endonuclease
• CPC Class Codes: C12Q 2525/155 incorporating/generating a new priming site
• CPC Class Codes: C12Q 2525/191 incorporating an adaptor
• CPC Class Codes: C12Q 2535/113 Cycle sequencing
• CPC Class Codes: C12Q 2539/107 Representational Difference Analysis [RDA]
• CPC Class Codes: C12Q 2561/125 Ligase Detection Reaction [LDR]
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides
• CPC Class Codes: C12Q 2565/514 characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The present invention is directed to a method of assembling genomic maps of an organism'"'"'s DNA or portions thereof. A library of an organism'"'"'s DNA is provided where the individual genomic segments or sequences are found on more than one clone in the library. Representations of the genome are created, and nucleic acid sequence information is generated from the representations. The sequence information is analyzed to determine clone overlap from a representation. The clone overlap and sequence information from different representations is combined to assemble a genomic map of the organism. Once the genomic map is obtained, genomic sequence information from multiple individuals can be applied to the map and compared with one another to identify single nucleotide polymorphisms. These single nucleotide polymorphisms can be detected, and alleles quantified, by conducting (1) a global PCR amplification which creates a genome representation, and (2) a ligation detection reaction process whose ligation products are captured by hybridization to a support.

Claims

1. A method for large scale detection of single nucleotide plymorphisms on a DNA array comprising:

creating a repsentation of the genome from a clinical sample, wherein said creating comprises;

subjecting the clinical sample to treatment with a first restriction endonuclease under conditions effective to cleave DNA so that a first non-palindromic overhang is created in the clinical sample;

subjecting the clinical sample to treatment with one or more second restriction endonuclease under conditions effective to cleave DNA so that a second overhang is created in the clinical sample;

adding complementary linker adapters to the first overhang and complementary linker adpaters to the second overhang, in the presence of a ligase, the first restriction endonuclease, and the one or more second restriction endonuclease to bind the complementary linker adapters, respectively, to the first and second overhangs; and

adding PCR primers “

and amplifying fragments from the restriction endonuclease treatment to generate”

a representation of the genome in the form of nucleic acid target sequences;

providing a plurality of oligonucleotide probe sets, each set characterized by (a) a frist oligonucleotide probe, having a target-specific portion and an addressable array-specific portion, and (b) a second oligonuclotide probe, having a target-specific portion and a detectable reporter label, wherein the oligonueotide probes in a particular set are suitable for ligation together when hybridized adjacent to one another on a corresponding target sequence, but have a mismatch which interferes with such ligation when hybridized to any other nucleic acid sequence present in the representation;

providing a ligase;

blending the representation of the genome in the form of nucleic acid target sequences, the plurality of oligonucleotide probe sets, and the ligase to form a mixture;

subjecting the mixture to one or more ligase detection reaction cycles comprising a denaturation treatemtn, wherein any hybridized oligonucleotides are seprated from the target sequences by heating, and hybridization treatment, wherein the oligonucleotide probe sets hybridize at adjacent positions in a base-specific manner to their respective target sequences, if present in the sample, and ligate to one another at their junction to form a ligated product sequence containing (a) the addressable array-specific portin, (b) the target-specific portions connected together, and (c) the detectable reporter label, and, wherein the oligonucleotide probe sets may hybridize to nucleic acid sequences in the representation of the genome other than their respective target sequences but do not ligate together due to a presence of noe or more mismatches proximate their junction and individually separate during the denaturation treatement;

providing a support with different capture oligonucleotides immobilized at particular sites, wherein the capture oligonucleotides have nucleotide sequences complementary to the addressable array-specific portions;

contacting the mixture, after said subjecting, with the support under cinditions effective to hybridize the addressable array-specific portions to the capture oligonucleotides in a base-specific manner, thereby capturing the addressable array-specific portions on the support at the site with the complementary capture oligonucleotide; and

detecting the reporter lables of ligated product sequences captured on the support at particular sites, therby indicating the presence of single nucleotide polymorphisms.

2. A method according to claim 1, wherein the oligonucleotide probes in a set are suitable for ligation together at a ligation junction when hybridized adjacenty to one another on a corresponding target nucleotide sequence due to perfect complementarity at the ligation junction, but, when the olignucleotide probes in the set ar hybirdized to any other nucleotide sequence present in the sample, have a mismatch at a bse at the ligtion njunction which interferes with such ligation.

4. A method according to claim 1, wherein the first restriction endonuclease creates 2 base degenerate overhangs in the clinical sample and 1 to 12 non-palindromic linker adapters, which contain single stranded overhangs of the formula NN/N′

N′

where NN/N′

N′

is selected from the group consisting of AA/TT, AC/GT, AG/CT, CA/TG, GA/TC, and GG/CC, are used.

5. A method according to claim 1, wherein the first restriction endonuclease creates 3 base degenerate overhangs in the clinical sample and 1 to 16 non-palindromic complementary linker adapters, which contain single stranded overhangs of the formula NAA, NAC, NAG, NAT, NCA, NCC, NCG, NCT, NGA, NGC, NGG, NGT, NTA, NTC, NTG, and NTT, with N being any nucleotide, are used.

6. A method according to claim 1, wherein the first restriction endonuclease is selected from the group consisting of DrdI, BglI, DraIII, AlwNI, PflMI, SanDI, SexAI, PpuI, AvaII, EcoO109, Bsu361, BsrDI, BsgI, BpmI, SapI, and an isoschizomer thereof and the one or more second restriction endonuclease is MaeII, MspI, BfaI, HhaI, HinP1I, Csp61, TaqI, MseI, or an isoschizomer thereof.

8. A method according to claim 1, wherein PCR primers amplify fragments from the restriction endonuclease digerst as a representation and size selection of approximately 200 to 2,000 bp is applied prior to amplification, improving the yield of fragments in the representation.

9. A method according to claim 1, wherein a single linker adapter primer is used to select fragments containing only one of the overhangs and a PCR primer complementary to this linker adapter with one addtional selective base on the 3′

end is used during the PCR amplification step.

10. A method according to claim 1, wherein more than one linker-adapter primer is used to select fragments containing some of the overhangs and PCR primers complementary to the more than one linker adapter with one additional selective base on the 3′

end are used.

11. A method according to claim 1, wherein PCR primers amplify fragments from the restriction endonuclease digest as a representation and a single liner-adapter primer is used to select fragments containing only one of the overhangs and PCR primers complementatry to this linker adapter with one additional selective base on the 3′

end are used.

12. A method according to claim 1, wherein the PCR primers amplify fragments from the restriction endonuclease digest as a representation and a single linker-adapter primer is used to selct fragments containing only one fo the overhangs and PCR primers complementary to this linker adapter with two addtional selective bases on the 3′

end are used during the PCR amplicfication step.

13. A method according to claim 1, wherein the target-specific portion of the first oligonucleotide probe is complementary to a first allele, while the addressable array-specific portion is a first addressable array-specific portion and each set of oligonucleotide probes further compises a third oligonucleotide probe, having a target-specific portion complementary to a second allele and a second addressable array-specific portion, wherein the first and second oligonucleotide probes of a particular set are sutable for ligation together when hybridized adjacetn to one another on a corresponding first allele target nucleotide sequence, wherein the second and third oligonucleotide probes of a particular set are suitable for ligation together whenn hybridize adjacent to one another on a corresponding second allele target nucleotide sequence, but each set has a mismatch which interferes with such ligation when hybridized to any other nucleotide sequence present in the representation of the sample and, wherein the reporter lables of ligation product sequences are captured to the support at particular sites during said detecting, where the presence of reporter label at the complement of the frist addressable array-specific portion indicates the presence of the first allele, while presene of reporter label at the complement of the second addressable array-specific portion indicates the presence of the second allele, for each set, therby indicating allele differences.

14. A method according to claim 13, wherein the oligonucleotide probes in a set are suitable for ligation together at a ligation junction when hybridized adjacent to one another on a corresponding target nucleotide sequence due to perfect complementarity at athe ligation junction, but, when the oligonucleotide probes in the set ar hybridized to any other nucleotide sequence presetn in the sample, have a mismatch at a base at the lgation junction which interferes with such ligation.

15. A method according to claim 13, wherein the mismatch is at the 3′

base at the ligation junction.

16. A method according to claim 13, wherein the first and second alleles differ by a single nucleotide.

17. A method according to claim 13, wherein said method is used to quantify an allele imbalance between first and second alleles and the different capture oligonucleotides immobilized at particular sites are the same for both the first allele target nucleotide sequence and the second allele target nucleotide sequence, wherein the oligonucleotide probe sets have either of two reporter labels which can be detected and distinguished independently so that ligation product sequences for the first allele target nucleotide sequence and the second allele target nucleotide sequence are captured on the support with the ratio of the first reporter lable to the second reporter label at the complement of the first addressable array-specific portion divided by the ratio of the first reporter lable to the second reporter lable at the complement of the second addressable array-specific portion reflecting an initial allele ratio for each test and normal allele position and the relative imbalance of the first and second alleles in a test sample is determined by dividing the initial allele ratio for the test sample by the initial allele ratio for a normal sample, whereby (1) a ratio of >

1 indicates that the first allele is in that number-fold greater in quantity than the second allele, (2) a ratio of <

1 indicates that the second allele is in the inverse number-fold greater in quantity thatn the first allele, and (3) a ratio of about 1 indicates the first and second allele are present in about the same quantity.

18. A method according to claim 17, wherein said method is for quantifying loss of heterozygosity (LOH) or gene amplification in a tumor sample containing up to 50% stromal contamination by comparing allele imbalance at a tumor gene locus with allele balance at a control gene locus among a tumor and normal sample form the same individual and the different capture oligonucleotides immpobilized at particular sites are the same for both the first allele target nucleotide sequence and the second allele target nuclotide sequence, the two alleles being heterozygous at bouth the tumor gene locus and the control gene locus with the ratio of the first reporter lable to the second reporter label at the complementof the the first addressable array-specific portion for the tumor gene locus diveided by the ratio of the first reporter lable to the second reporter label at the complement of the first addressable array-specific portion for the control gene locus reflecting an initial tumor to control first allele ratio, wherein for both test and normal samples where the ratio of the first reporter label to the second reporter label at the complement of the second addressable array-specific portion for the tumor gene locus divided by the ratio of the first reporter label to the second reporter label at the complement of the second addressable array-specific portion for the control gene locus reflects an initial tumor to control second allele ratio and a presence of gene amplification or LOH of the frist and second tumor alleles in the tumor sample is determined by dividing the intial tumor to control level for a given allele ratio for the tumor sample by the initial tumor to control level for a given allele ratio for the normal sample where (1) a ratio of >

2 for a first tumor gene allele indicates the first tumor gene allele is amplified in the tumor sample, compared with the normal sample, (2) a ratio of >

2 for a second tumor gene allele indicates the second tumor gene allele is amplified in the tumor sample, comapred with the normal sample, (3) a ratio of <

0.5 for a first tumor gene allele shows that the first tumor gene allele underwent LOH in the tumor sample, compared with the normal sample, (4) a ratio of <

0.5 for a second tumor gene allele shows that the second tumor gene allele underwent LOH in the tumor sample, compared with the normal sample, and (5) a ratio of about 1 indicates a given tujor allele did not undergo LOH or amplification, compared with the normal sample.

19. A method according to claim 13, wherein the method is utilized for quantifying an allele imbalance between a test sample and a normal sample with each set characterized by both first and second oligonucleotide probes, a percentage of each have a second distict detectable reporter label, wherein the two reporter labels may be detected and distinguished independently such that the ratio of the first reporter label to the second reporter label at the complement of the first addressable array-specific portion divided by the ratio of the first reporter label to the second reporter lable at the complement of the second addressable array-specific portion reflects an initial allele ratio for each test and normal allele position and a releative imbalance of the first and second alleles in the test sample is determined by dividing the initial allele ratio for the test sample by the initial allele ratio for the normal sample, wherein (1) a ratio of >

1 indicates that the first allele is in that number-fold greater in quantity than the second allele, (2) a ratio of <

1 indicates that the second allele is in the inverse number-fold greater in quantity than the first allele, and (3) a ratio of ablut 1 indicates that the first and second allele are present in ablut the same quantity, indicating there is no allele imbalance compared with the normal sample.

20. A method according to claim 19, wherein said method is carried out for quantifying loss of heterozygosity (LOH) or gene amplification in a tumor sample containing up to 50% stromal contamination by comparing allele imbalance at a tumor gene locus with allele balance at a control gene locus among a tumor and normal sample form the same individual with the two alleles being heterozygous at both the tumor gene locus and the cotrol gene locus and the ratio of the first reporter label to the second reporter label at the complement of the first addressable array-specific portion for the tumor gene locus divided by the ratio of the first reporter label to the second reporter label at the complement of the first addressable array-specific portion for the control gene locus reflecting an initial tumor to control first allele ratio, such that for both test and normal samples, the ratio of the first reporter label to the second reporter label at the complement of the second addressable array-specific portion for the tumor gene locus divided by the ratio of the first reporter label to the second reporter label at the complement of the second addressable array-specific portion for the control gene locus reflects an initial tumor to control second allele ratio and the presence of gene amplification or LOH of the first and second tumor alleles in the tumor sample is determined by dividing the initial tumor to control for a give allele ratio for the tumor sample by the intitial tumor to control for a give allele ratio for the normal sample, wherein (1) a ratio of >

2 for a first tumor gene allele indicates the first tumor gene allele is amplified in the tumor sample, compared with the normal sample, (2) a ratio of >

2 for a second tumor gene allele indicates the second tumor gene allele is amplified in the tumor sample, compared with the normal sample, (3) a ratio of <

0.5 for a first tumor gene allele indicates the first tumor gene allele underwent LOH in the tumor sample, compared with the normal sample, (4) a ratio of <

0.5 for a second tumor gene allele indicates the second tumor gene allele underwent LOH in the tumor sample, compared with the normal sample, and (5) a ratio of about 1 indicates a given tumor allele did not undergo LOH or amplification, compared with the normal sample.

21. A method according to claim 1, wherein the target-specific portion of the second oligonucleotide probe is complementary to a first allele and the detectable reporter label of the second oligonucleotide probe is a first detectable reporter label adn each set of olignucleotide probes further comprises a third oligonucleotide probe, having a target specific portion complementary to a second allele and a second detectable reporter label, wherein the first and second oligonucleotide probes of a particular set are suitable for ligation together when hybridized adjacent to one another on a corresponding first allele target nucleotide sequence, wherein the frist and third oligonucleotide probes of a prticular set are suitable for ligation toether when hybridized adjacent to one another on a corresponding second allele target nucleotide sequence, but each set has a mismatch which interferes with such ligation when hybridized to any other nucleotide sequence present in the representation of the sample with the two reporter labels being detected and distinguished independently such that detection of the first reporter label at the complement of the addressable array-specific portion indicates a presence of the first allele, while detection of the second reporter label at the complement of the addressable array-specific portion indicates a presence of the second allele, for each set.

22. A method according to claim 21, wherein the mismatch is at a 3′

base at the ligation junction.

23. A method according to claim 21, wherein the first and second alleles differ by a single nucleotide.

24. A method according to claim 21, wherein said method is used to quantify an allele imbalance between first and second alleles and the different capture oligonucleotides immobilized at particular sites are the same for both the first allele target nucleotide sequence and the second allele target nucleotide sequence, wherein the oligonucleotide probe sets have either of two reporter labels which can be detected and distinguished independently so that ligation producet sequences for the first allele target nucleotide sequence and the second allele target nucleotide sequence are captured on the support at particular sites with the ratio of the first reporter label to the second reporter label at the complement of the first addressable array-specific portion divided by the ratio of teh first reporter label to the second reporter label at the complement of the second addressable array-specific portion reflecting an initial allele ratio for each test and normal allele position and the relative imbalance of the frist and second alleles in the test sample is determined by dividing the initial allele ratio for the test sample by the initial allele ratio for the normal sample, whereby (1) a ratio of >

1 indicates that the first allele is in the number-fold greater quantity over the second allele, (2) a ratio of <

1 indicates that the allele is in the inverse number-fold greater quiantity over thge first allele, and (3) a ratio of about 1 determines the first and second allele are present in about the same quantity.

25.A method according to claim 21, wherein said method is for quantifying loss of heterozygosity (LOH) or gene amplification in a tumor sample containing up to 50% stromal contamination by comparing allele imbalance at a tumor gene locus with allele balance at a control gene locus among a tumor and normal sample from the same individual and the different capture oligonucleotides immobilized at particular sites are the same for both the first allele target nucleotide sequence and the second allele target nucleotide sequence, the tow alleles being heterozygous at bvouth the tumor gene locus and the control gene locus with the ratio of the first reporter label to the second reporter label at the complement of the first addressable array-specific portion for the tumor gene locus divided by the ratio of the first reporter label to the second reporter label at the complement of the first addressable array-specific portion for the control gene locus reflecting an initial tumor to control first allele ratio, wherein for both test and normal sample where the ratio of the first reporter label to the second reporter label at the complement of the second addressable array-specific portion for the tumor gene locus divided by the ratio of the firs reporter label to the second reporter label at the complement of the second addressable array-specific portion for the control gene locus reflects an initial tumor to control second allele ratio and a presence of gene amplification or LOH of the first and second tumor alleles in the tumor sample is determined by dividing the initial tumor to control level for a given allele ratio for the tumor sample by the initial tumor to control level for a given allele ratio for the normal sample where (1) a ratio of >

2 for a first tumor gene allele indicates the first tumor gene allele is amplified in the tumor sample, compared with the normal sample, (2) a ratio of >

2 for a second tumor gene allele indicates the secdond tumor gene allele is amplified in the tumor sample, compared with the normal sample, (3) a ratio of <

0.5 for a first tumor gene allele determines the first tumor gene allele underwent LOH in the tumor sample, compared with the normal sample, (5) a ratio of about 1 determines a given tumor allele did not undergo LOH or amplification, compared with the normal sample.

25. A method according claim according to claim 21, wherein the method is utilized for quantifying an allele imbalance between a test sample and a normal sample with each set characterized by both first and second oligonucleotide probes, a percentage of each have a second distinct detectable reporter label, wherein the two reporter labels may be detected and distinguished independently such that the ratio of the first reproter label to the second reporter label at the complement of the first addressable array-specific portion divided by the ratio of the first reporter label to the second reporter label at the complement of the second addressable array-specific portion reflects an intitial allele ratio for each test and normal allele position and the relative imbalance of the first and second alleles in the test sample is determined by dividing the initial allele ratio for the test sample by the initial allele ratio for the normal sample, wherein (1) a ratio of >

1 indicates that the first allele is in that number-fold greater quantity over the second allele, (2) a ratio of <

1 indicates that the second allele is in the inverse number-fold greater quantity over the first allele, and (3) a ratio of about 1 indicates that the first and second allele are present in about the same quantity, indicating there is no allele imbalance compared with the normal sample.

26. A method according to claim 21, wherein said method is carried out for quantifying loss of heterozygosity (LOH) or gene amplification in a tumor sample containing up to 50% stromal contamination by comparing allele imbalance at a tumor gene locus with allele balance at a control gene locus among a tumor and normal sample from the same individual with the two alleles being heterozygous at bouth the tumor gene locus and the control gene locus and the ratio of the first reporter label to the secvond reporter label at the complement of the first addressable array-specific portion for the tumor gene locus divided by the ratio fo the first reporter label to the second reporter label at the complement of the first addressable array-specific portion for the control gene locus reflecting an initial tumor to control first allele ratio, such that for both test and normal sample, the ratio of the first reporter label to the second reporter label at the complement of the second addressable array-specific portion for the control gene locus reflects an initial tumor to control second allele ratio and the presence of gene amplification or LOH of the first and second tumor alleles in the tumor sample is determined by dividing the initial tumor to control for a given allele ratio for the tumor sample by the initial tumor to control for a given allele ratio for thr normal sample, wherein (1) a ratio of >

2 for a first tumor gene allele indicates the first tumor gene allele is amplified in the tumor sample, compared with the normal sample, (2) a ratio of >

2 for a second tumjor gene allele indicates the second tumor gene allele is amplified in the tumor sample, compared with the normal sample, (3) a ratio of <

0.5 for a first tumor gene allele indicates the first tumor gene allele underwent LOH in the tumor sample, compared with the normal sample, (4) a ratio of <

0.5 for a second tumor gene allele indicates the second tumor gene allele underwent LOH in the tumor sample, compared with the normal sample, and (5) a ratio of about 1 indicates a given tumor allele did not undergo LOH or amplification, compared with the normal sample.

27. A method according to claim 1, wherein the ligase is thermostable.

3. A method according to calim 2, wherein the mismatch is at the 3′

base at the ligation junction.

7. A method according to calim 1, wherein the first restriction endonuclease is BamHI, AvrII, NheI, SpeI, XbaI, KpnI, SphI, AatII, AgeI, XmaI, NgoMI, BspEI, NluI, SacII, BsiWI, PstI, ApaLI, or isoschizomers thereof.